Heart Transplant Infection
11
4
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
45%
5 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
TTV Viral Load in Heart Transplant Recipients
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Letermovir Use in Heart Transplant Recipients
Intestinal Microsporidiosis in French Heart Transplant Recipients (CARMIC)
Levothyroxine Supplementation for Heart Transplant Recipients
Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response
Transplantation Using Hepatitis C Positive Donors, A Safety Trial